New Journal Website is available at: http://www.journalonweb.com/rcm

Published by: Shiraz University of Medical Sciences

Galectin-3 Serum Levels Are Independently Associated With Microalbuminuria in Chronic Heart Failure Outpatients

Massimo Iacoviello 1 , * , Nadia Aspromonte 2 , Marta Leone 3 , Valeria Paradies 3 , Valeria Antoncecchi 3 , Roberto Valle 4 , Pasquale Caldarola 5 , Marco Matteo Ciccone 3 , Loreto Gesualdo 6 and Francesca Di Serio 7
Authors Information
1 Department of Cardiothoracic, Cardiology Unit, Policlinic University Hospital, Bari, Italy
2 DEA Department, Cardiology Unit, San Filippo Neri Hospital, Rome, Italy
3 Department of Emergency and Organ Transplantation, School of Cardiology, University of Bari, Bari, Italy
4 Cardiology Unit, Hospital Department, Chioggia ULSS 14, Chioggia, Italy
5 Cardiology Unit, Cardiology Department, San Paolo Hospital, Bari, Italy
6 Department of Diagnostic Pathology, Bioimages and Public Health, Policlinic University Hospital, Bari, Italy
7 Clinical Pathology Unit, University of Bari, Bari, Italy
Article information
  • Research in Cardiovascular Medicine: February 2016, 5 (1); e28952
  • Published Online: December 14, 2015
  • Article Type: Brief Report
  • Received: April 13, 2015
  • Revised: May 11, 2015
  • Accepted: June 7, 2015
  • DOI: 10.5812/cardiovascmed.28952

To Cite: Iacoviello M, Aspromonte N, Leone M, Paradies V, Antoncecchi V, et al. Galectin-3 Serum Levels Are Independently Associated With Microalbuminuria in Chronic Heart Failure Outpatients, Res Cardiovasc Med. 2016 ;5(1):e28952. doi: 10.5812/cardiovascmed.28952.

Abstract
Copyright: Copyright © 2016, Research in Cardiovascular Medicine. .
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004; 110(19): 3121-8[DOI][PubMed]
  • 2. Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013; 6(1): 107-17[DOI][PubMed]
  • 3. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010; 12(8): 826-32[DOI][PubMed]
  • 4. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010; 99(5): 323-8[DOI][PubMed]
  • 5. Gopal DM, Kommineni M, Ayalon N, Koelbl C, Ayalon R, Biolo A, et al. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc. 2012; 1(5)[DOI][PubMed]
  • 6. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008; 172(2): 288-98[DOI][PubMed]
  • 7. O'Seaghdha CM, Hwang SJ, Ho JE, Vasan RS, Levy D, Fox CS. Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol. 2013; 24(9): 1470-7[DOI][PubMed]
  • 8. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1992; 340(8815): 319-23[PubMed]
  • 9. Iacoviello M, Puzzovivo A, Guida P, Forleo C, Monitillo F, Catanzaro R, et al. Independent role of left ventricular global longitudinal strain in predicting prognosis of chronic heart failure patients. Echocardiography. 2013; 30(7): 803-11[DOI][PubMed]
  • 10. Fallahzadeh MK, Sagheb MM, Fallahzadeh MH. In memorandum of world kidney day: chronic kidney disease: a common but often unnoticed major health problem. Iran Red Crescent Med J. 2011; 13(3): 164-6[PubMed]
  • 11. Iacoviello M, Leone M, Antoncecchi V, Ciccone MM. Evaluation of chronic kidney disease in chronic heart failure: From biomarkers to arterial renal resistances. World J Clin Cases. 2015; 3(1): 10-9[DOI][PubMed]
  • 12. Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet. 2009; 374(9689): 543-50[DOI][PubMed]
  • 13. Niizeki T, Takeishi Y, Sasaki T, Kaneko K, Sugawara S, Watanabe T, et al. Usefulness of albuminuria as a prognostic indicator in patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2013; 111(8): 1180-6[DOI][PubMed]
  • 14. Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G, De Zeeuw D, De Jong PE. Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol. 2000; 11(10): 1882-8[PubMed]
  • 15. Okamura DM, Pasichnyk K, Lopez-Guisa JM, Collins S, Hsu DK, Liu FT, et al. Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Renal Physiol. 2011; 300(1)-53[DOI][PubMed]
  • 16. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009; 230(1): 160-71[DOI][PubMed]
  • 17. Varin R, Mulder P, Tamion F, Richard V, Henry JP, Lallemand F, et al. Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure : role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation. 2000; 102(3): 351-6[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader